Focus Formula Review

The United States Food and Drug Administration (FDA) has approved Paxil as a suitable prescription for depression in adults over the age of 18. Paxil, however, still has yet to gain FDA approval for children and teenagers under the age of 18 as it has been shown that Paxil Can Cause Neonatal Abstinence Syndrome. There has also been seen that the manufacturer of Paxil, GlaxoSmithKline, has tampered with case study results with regards to the drug’s safety and efficacy.

This particular study which is named Paxil Study 329, was published in the Journal of the American Academy of Child and Adolescent Psychiatry in 2001. It claimed that Paxil was good for treating depression in kids and that patients didn’t suffer many adverse effects from taking the drug. This information can be misleading however as more recent studies have shown that Paxil actually has the potential to raise suicidal tendencies in children by as much as 5%.

Another problem that has occurred in this study is that the authors whose names that have been placed on this particular study were not the ones who wrote the results. This means that the study was actually ghost written. Meaning that another writer was paid to write and publish the results using the other author’s names. This could indicate that the authors whose names appear on the study may not have known the information contained in the study itself.

However, what seems to be the most concerning problem with study 329 is that the researchers carefully chose the data to present only the data in the published study that were most favorable to the drug that was featured and paid for the study, namely Paxil. If researchers conceal the true design of a study (or negative data), then journals will not be able to get the complete picture. {Meaning the medical journals publish such a picture not knowing the whole truth.}

Paxil Study 329’s results have been found to be misleading to the public; and have been mentioned in several Paxil Birth Defect Lawsuits. To date Paxil has yet to gain FDA approval for use with children and teenagers under the age of 18.